Binyam Yilma
0009-0007-8845-5390
Publication & Citation Trends
Publications
0 total
Abstract 2968: EGFR S442 mutation confers cetuximab resistance that can be overcome by ERBB2 blockade by trastuzumab-deruxtecan.
Cited by 0
Semantic Scholar
Landscape of somatic genetic alterations and PAM50 intrinsic subtypes in breast cancer associated with germline pathogenic variants in DNA-repair genes.
Cited by 0
Semantic Scholar
Real-World Clinical Effectiveness and Migraine-Related Healthcare Resource Utilization in Patients Initiating Fremanezumab in Germany and the United Kingdom
Cited by 0
Semantic Scholar
Abstract 1711: Genomic and transcriptomic mediators of resistance to antibody-drug conjugates (ADCs) in metastatic breast cancer (MBC): A comprehensive multi-center study
Cited by 2
Semantic Scholar
ESR1 mutations and associated alterations in patients with estrogen receptor (ER+), HER2-positive (HER2+) breast cancers at diagnosis of metastatic disease (mBC).
Cited by 0
Semantic Scholar
Genomic Landscapes of Early-Onset Versus Average-Onset Colorectal Cancer Populations OA
Cited by 8
Semantic Scholar
The chromatin remodeling protein ARID1A is required for MLL-AF9 leukemogenesis
Cited by 0
Semantic Scholar
Molecular characteristics of early-onset versus average-onset gastroesophageal adenocarcinoma.
Cited by 0
Semantic Scholar
Research Topics
Drug Transport and Resistance Mechanisms
(37)
RNA Interference and Gene Delivery
(27)
Cancer therapeutics and mechanisms
(23)
Ferrocene Chemistry and Applications
(11)
DNA and Nucleic Acid Chemistry
(10)
Affiliations
Harvard University
Colby–Sawyer College
Tempus Labs (United States)
Dana-Farber Cancer Institute
Analysis Group (United States)